NIH Updates its Position on Ivermectin

The NIH has issued a statement on Ivermectin a antiparasitic agent  a pill sometimes used to treat children with head lice or to rid dogs and cats of worms and prevent diseases related to parasites in humans, and pets has been touted  as a possible treatment for COVID-19 showing promising results in lab studies. The National Institute of health previous position , dated August 27, recommended against Ivermectin. now it has updated its position “As such, the Panel has determined that there are insufficient data to recommend either for or against the use of ivermectin for the treatment of COVID-19.”

The Buffalonews reports a judge ordered a  hospital to use the experimental Covid-19 treatment, on a women whose family say saved her life “This lady was on a ventilator, literally on her deathbed, before she was given this drug,”  “As far as we’re concerned, the judge’s order saved this woman’s life.” 

NIH statement continues "Since the last revision of the Ivermectin section of the Guidelines, results from several randomized clinical trials and retrospective cohort studies of ivermectin use in patients with COVID-19 have been published in peer-reviewed journals or made available as non-peer-reviewed manuscripts. Updates to the Ivermectin section that are underway will include discussion of these studies. Because many of these studies had significant methodological limitations and incomplete information, the Panel cannot draw definitive conclusions about the clinical efficacy of ivermectin for the treatment of COVID-19.” NIH concludes from its current analysis that, “results from adequately powered, well-designed, and well-conducted clinical trials are needed to provide further guidance on the role of ivermectin in the treatment of COVID-19.”